Ketamine for the Treatment of Opioid Use Disorder and Depression

Brief Summary

The purpose of the study is to examine whether an investigational medication called ketamine is able to improve treatment outcomes for concurrent opioid addiction and depression when used in conjunction with buprenorphine treatment. Study medications will be delivered twice per week for four weeks. If you are eligible and you decide to enroll in the study, your participation will last approximately 8 weeks, or 2 months.

Intervention / Treatment

  • Drug: Ketamine Hydrochloride
  • Drug: Placebo

Condition or Disease

  • Depression
  • Opioid-use Disorder
  • Opioid Abuse

Phase

Study Design

Study type: Interventional
Status: Not yet recruiting
Study results: No Results Available
Age: 18 Years to 65 Years   (Adult, Older Adult)
Enrollment: 30 ()
Funded by: Other|NIH

Masking

Clinical Trial Dates

Start date: Aug 30, 2020
Primary Completion: Dec 01, 2021
Completion Date: Dec 01, 2021
Study First Posted: Nov 26, 2019
Results First Posted: Aug 31, 2020
Last Updated: Aug 10, 2020

Sponsors / Collaborators

Lead Sponsor: N/A
Responsible Party: N/A

Eligibility Criteria

Sex: All
Minimum Age: 18
Maximum Age: 65

More Details

NCT Number: NCT04177706
Other IDs: 00091292|K12DA031794
Study URL: https://ClinicalTrials.gov/show/NCT04177706
Last updated: Jun 17, 2022